The Possible Role of Tumor Necrosis Factor-α in Diabetic Polyneuropathy by Satoh, Jo et al.
Experimental Diab. Res., 4:65–71, 2003
Copyright c  Taylor and Francis Inc.
ISSN: 1543-8600 print / 1543-8619 online
DOI: 10.1080/15438600390228496
REVIEW
The Possible Role of Tumor Necrosis Factor-α
in Diabetic Polyneuropathy
Jo Satoh,1 Soroku Yagihashi,2 and Takayoshi Toyota3
1Division of Molecular Metabolism and Diabetes, Department of Internal Medicine,
Tohoku University Graduate School of Medicine, Sendai, Japan
2The First Department of Pathology, Hirosaki University School of Medicine, Hirosake, Japan
3Tohoku Rosai Hospital, Sendai, Japan
In this review, the authors provide evidences that im-
ply the role of tumor necrosis factor-α (TNF-α)i nt h e
pathogenesis of diabetic complications, especially diabetic
polyneuropathy. Under chronic hyperglycemia, endoge-
nousTNF-αproductionisacceleratedinmicrovascularand
neural tissues, which may undergo an increased microvas-
cular permeability, hypercoagulability, and nerve damage,
thus initiating and promoting the development of charac-
teristic lesions of diabetic microangiopathy and polyneu-
ropathy. Enhanced TNF-α production may also promote
atherosclerosis due to increased insulin resistance and the
expression of adhesion molecules. Clinical application of
speciﬁc agents that suppress production and/or activity
of TNF-α may inhibit the development and exacerbation
of chronic diabetic complications.
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Tumor necrosis factor-α (TNF-α) was originally discov-
ered as a monokine produced by macrophages. It was sub-
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sequently revealed that various cells, such as ﬁbroblasts, ep-
ithelial cells, adipocytes, and myocytes, also produce TNF-α,
which has a variety of biological activities. It has been indi-
cated that TNF-α plays a role in the pathogenesis of not only
type 1 diabetes mellitus [1] but also type 2 diabetes mellitus
[2]. Recent studies have further disclosed that this peptide con-
tributes to the development of diabetic complications [3, 4].
In this review, we propose a hypothesis on a possible role of
TNF-α inchronicdiabeticcomplications,especiallyindiabetic
polyneuropathy.
INCREASED PRODUCTION OF TNF-α
IN A DIABETIC STATE
DuringthestudyontheroleofTNF-α intype1diabetes[5],
we incidentally found that lipopolysaccharide (LPS)-induced
serumTNF-α signiﬁcantlyincreasedinvivoinananimalmodel
of diabetes after development of diabetes, irrespective of the
type of diabetes, i.e., BB rats and NOD mice for a model of
type 1 diabetes and GK rats for a model of type 2 [6]. Serum
TNF-α levels were also higher in patients with type 2 dia-
betes than those in nondiabetic patients [7]. Thus, in vivo pro-
duction of TNF-α is increased under chronic hyperglycemia.
The mechanisms of enhanced TNF-α production may be as-
cribed to macrophage stimulation by high glucose itself [8],
hyperglycemia-induced oxidative stress [9], or exposure to ad-
vancedglycationendproducts(AGEs)[10].Theincreasedpro-
ductionofTNF-αinvivomayexacerbateinsulinresistance[11]
and eventually promote diabetic complications as discussed
below.
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TNF-α and Insulin Resistance
Increased TNF-α production secondary to hyperglycemia
may be a factor that exacerbates insulin resistance in poorly
controlled diabetes because TNF-α induces insulin resistance
[2, 11]. Hotamisligil and Spiegelman reported that TNF-α
mRNA and protein expression increases in the adipocytes of
obeseanimalsandTNF-α inducesinsulinresistanceinthemus-
cles and the adipocytes themselves in paracrine and autocrine
fashions [2]. The molecular mechanisms by which TNF-α in-
duces insulin resistance are considered to be the following.
TNF-α binds TNF receptor 1 and activates sphingomyelinase
thatmetabolizessphingomyelintoceramide[12].Ceramidein-
creases serine phosphorylation of insulin receptor substrate-1
(IRS-1), which inhibits the insulin receptor tyrosine phospho-
rylation, resulting in attenuation of insulin signaling and a
decrease in glucose transporter-4 (GLUT-4) translocation and
glucose uptake. TNF-α–mediated insulin resistance associated
with obesity may be related to metabolic syndrome [2]. Insulin
resistance related to TNF-α in obese animals has also been
reported in obese humans [13].
TNF-α and Chronic Diabetic Complications
Chronic hyperglycemia activates macrophages [8–10] and
stimulates in vivo TNF-α production [6, 7]. Enhanced TNF-α
production in a diabetic state may promote the development
of diabetic micro- and macroangiopathies through a variety of
TNF-α bioactivities. For example, TNF-α increases the per-
meability of the endothelium through release of nitric oxide
[14] and increases thrombogenesis through plasminogen acti-
vator inhibitor-1 (PAI-1) overexpression [15]. A role of TNF-α
in angiopathies is supported by a report in which cerebral is-
chemia is reduced by neutralizing serum TNF-α with speciﬁc
antibody in spontaneously hypertensive rats [16]. Furthermore,
TNF-α stimulates the expression of adhesion molecules on
the endothelial cells [17]. The serum levels of free adhesion
molecules (vascular cell adhesion molecule-1, VCAM-1) sig-
niﬁcantly correlate with the intima-media complex thickness
(IMT) of the carotid artery [18]. These imply that TNF-α ac-
celeratesatherosclerosisbyinducingtheexpressionofadhesion
molecules on the endothelial cells.
SUPPRESSION OF DIABETIC
COMPLICATIONS BY INHIBITING TNF-α
PRODUCTION
BasedonthehypothesisthatTNF-α isalsoimplicatedinmi-
crovascular complications in diabetes, we administered TNF-α
to diabetic rats and measured the motor nerve conduction ve-
locity (MNCV) of the sciatic nerve to explore the effect of
FIGURE 1
Suppression of motor nerve conduction velocity by TNF-α
administration in diabetic rats. Streptozotocin-induced
diabetic rats and nondiabetic rats were administered 1 × 105
units of recombinant human TNF-α and 6 hours later MNCV
of the tibial nerve was measured [19].
TNF-α on nerve function. Administration of TNF-α signiﬁ-
cantly decreased MNCV in diabetic rats (Figure 1), although it
didnotinﬂuencetheMNCVinnondiabeticrats[19].Thisﬁnd-
ing strongly implies that TNF-α contributes to diabetic nerve
dysfunction and indicates that suppression of enhanced TNF-α
production in a diabetic state might possibly attenuate the pro-
gressionofdiabeticpolyneuropathy.Totestthishypothesis,we
performed experiments using some reagents known to inhibit
TNF-α production [20–23].
Inhibition of Experimental Diabetic
Neuropathy with N-acetylcysteine (NAC)
NAC is a precursor of glutathione, which is important in the
redox reaction in cells and is clinically used as an antioxidant
for detoxication [24]. NAC is a free-radical scavenger that has
beenreportedtosuppressTNF-α productioninvitroandinvivo
[25].WecouldreproducetheinhibitoryeffectofNAConTNF-
α production in diabetic rats [26]. Lipopolysaccharide (LPS)-
induced serum TNF-α levels were signiﬁcantly increased in
streptozotocin-induced diabetic rats as compared with those in
nondiabetic control rats. In diabetic rats, glucose levels were
maintained at >300 mg/dL (16.7 mM) for 12 weeks of the ex-
perimental period. Although daily oral administration of NAC
didnotalterbloodglucoselevels,itdose-dependentlyinhibited
LPS-induced serum levels of TNF-α in diabetic rats [26].
Next,weobservedtheeffectofNAConMNCVandthemor-
phology of the sciatic nerve [20]. MNCV in nondiabetic rats
was increased with increasing age, whereas it was signiﬁcantly
decreased in diabetic rats. Daily administration of NAC dose-
dependently improved the decreased MNCV in diabetic rats.TNF-α IN DIABETIC POLYNEUROPATHY 67
Administration of NAC even after the development of nerve
dysfunction inhibited the further lowering of MNCV. Further-
more, the effects of NAC on delayed MNCV disappeared when
the drug was ceased to administer. These results indicate that
NAC administration has not only a preventive effect but also
a therapeutic effect on diabetic polyneuropathy. NAC adminis-
tration also inhibited morphological changes in the peripheral
nerve, that is, it prevented ﬁber atrophy and decreased ﬁber
density of myelinated nerve ﬁbers in diabetic rats [20]. Fre-
quencies of abnormal ﬁbers in teased ﬁber studies were also
less in NAC-treated rats compared with untreated rats [20].
With these beneﬁcial effects on neuropathic changes, NAC
administration improved enhanced TNF-α production, in-
creased serum peroxide and decreased glutathione content in
the erythrocytes [20]. However, NAC did not affect metabolic
changes such as increased glucose and sorbitol content and
decreased cyclic adenosine monophosphate (cAMP) in nerve
tissues [20]. It is therefore likely that the beneﬁcial effects of
NAC on diabetic nerve might be a result of inhibition of vas-
cular and nerve damage caused by increased TNF-α and free
radicals.
Inhibitory Effects of Clinical Agents on TNF-α
Production and Experimental Diabetic
Neuropathy
Inhibition of TNF-α Production With Various Clinical Agents
Because NAC, a TNF-α suppressant, inhibited diabetic
polyneuropathy in type 1 diabetic animal models, we screened
various clinical agents for TNF-α production in vitro and in
vivo. We found inhibitory effects on TNF-α of nicotinamide
[27], angiotensin-converting enzyme (ACE) inhibitors [28],
certain calcium channel blockers, and an alpha 1 receptor
blocker [29]. Among the hypoglycemic agents for diabetes
treatment, gliclazide (but not glibenclamide), sulfonylurea
derivatives, and troglitazone (an insulin-sensitizing thiazo-
lidinedione), had inhibitory effects on TNF-α production [30].
Wechosegliclazideandtroglitazone(troglitazonewaswith-
drawn from the market in March 2000 because of idiosyn-
cratic hepatotoxicity) for the treatment of experimental dia-
betic neuropathy because these oral hypoglycemic agents were
commonly used for diabetic patients. It has already been in-
dicated that an ACE inhibitor ameliorated peripheral neuropa-
thy in diabetic patients [31] and that clinical drugs that have
TNF-α–suppressingpotentialshavebeneﬁcialeffectsoninsulin
resistance [2].
Inhibition of Experimental Diabetic Neuropathy With
Antidiabetic Agents With TNF-α Suppressor Activity
Gliclazide. We studied the effects of antidiabetic agents
that suppress the TNF-α production. Streptozotocin-induced
diabetic rats were fed regular chow mixed with gliclazide or
glibenclamide. MNCV and TNF-α production were periodi-
cally measured and histologically observed at end nerve tissues
[21]. Compared with nondiabetic rats, blood glucose levels (of
∼300 mg/dL, 16.7 mM) increased 3 times, whereas serum in-
sulin levels decreased to 1/3 in diabetic rats. Neither gliclazide
nor glibenclamide affected blood glucose or insulin levels in
nondiabetic and diabetic rats. TNF-α production was enhanced
in diabetic rats compared with that in nondiabetic rats, and the
enhanced TNF-α production was suppressed in the gliclazide-
treated,butnottheglibenclamide-treated,rats.Increasedserum
peroxide levels in diabetic rats were also signiﬁcantly inhibited
with gliclazide but not with glibenclamide. Under these condi-
tions, gliclazide signiﬁcantly inhibited the lowering of MNCV
and the increase in myelinated ﬁber density in diabetic rats,
whereas glibenclamide did not ameliorate these abnormalities
[21].Thus,itisconceivablethatgliclazideisbeneﬁcialforneu-
ropathic changes via inhibition of TNF-α production and lipid
oxidation in a diabetic state.
Troglitazone. As was the case of NAC [20] and gliclazide
[21], we showed that troglitazone improved lowered MNCV
and the abnormal morphology of peripheral nerves in dia-
betic rats irrespective of blood glucose levels [22]. The effects
of troglitazone were associated with inhibition of enhanced
TNF-α production and increased lipid oxidation in serum and
nerve tissues [22].
Pentoxifylline. Pentoxifylline, which was known to in-
hibit TNF-α production and its action [32], also inhibited in-
creased TNF-α production and lowering of MNCV in diabetic
rats [23].
MECHANISMS OF ACTION OF TNF-α
SUPPRESSANTS IN THE INHIBITION
OF DIABETIC POLYNEUROPATHY
Macrophages, which are activated by high glucose [8], ox-
idative stress [9], and AGEs [10] in a diabetic state, may inﬁl-
trate into nerve tissues [33] and locally produce much TNF-α,
resulting in endothelial and nerve ﬁber damage. In addition,
it has been proposed that TNF-α stimulates the expression of
speciﬁc proteins relevant to cellular damage, such as aldose
reductase [34], protein kinase C [35], mitogen-activated pro-
tein (MAP) kinase [36] and inducible nitric oxide synthase
[14, 37], all of which potentially play a role in the pathogen-
esis of diabetic polyneuropathy [38]. During the pathologic
process, TNF-α may initiate and promote the development of
nerve dysfunction via various pathways. Microvascular dam-
age elicited by TNF-α may cause nerve ischemia and increased
vascularpermeability,thuspermittingexposureofharmfulsub-
stances to nerve ﬁbers. On the other hand, it is shown that local
TNF-α exerts demyelination by attacking Schwann cells [39].68 J. SATOH ET AL.
FIGURE 2
Hypothetical role of TNF-α in the pathogenesis of diabetic neuropathy and possible mechanisms of TNF-α suppressants in
inhibition of diabetic neuropathy.
However,precisemechanismsofhowTNF-α isresponsiblefor
the pathogenesis of diabetic polyneuropathy remain to be elu-
cidated. It is hypothesized that NAC, gliclazide, troglitazone,
and pentoxifyllin may have inhibited diabetic polyneuropathy
by suppressing TNF-α production and also possibly by scav-
enging free radicals. The hypothetical mechanisms of TNF-α
suppressantsininhibitingdiabeticpolyneuropathyareshownin
Figure 2.
TNF-α PROMOTER GENE POLYMORPHISMS
AND DIABETIC POLYNEUROPATHY
The human TNF-α gene is located in the short arm of chro-
mosome6andTNF-αproductionisgeneticallyinﬂuenced[40].
It has been reported that there are TNF-α promoter gene poly-
morphisms that affect TNF-α production and that the polymor-
phisms are associated with insulin resistance, autoimmune dis-
eases,andsusceptibilitytoinfectiousdiseases[41].Inaddition,
it has been suggested that there is an association of TNF-α re-
striction fragment length polymorphism (RFLP) with severity
of diabetic retinopathy [42]. Recently, Higuchi and his asso-
ciates found a high frequency (∼15%) of the novel TNF-α pro-
motergenepolymorphismsinJapanesepopulations[43].Based
on this report, we examined the relationship between the novel
polymorphisms and diabetic neuropathy and demonstrated that
theTNF-α promotergenepolymorphism,C(−857)T,issigniﬁ-
cantly associated with prolonged F-wave latency in the median
nerve,thatisasensitivemarkerofperipheralnervedysfunction,
inpatientswithtype2diabetes[44].Thesecircumferentialevi-
dencewarrantsthefurtherevaluationoftheroleofTNF-α gene
inclinicalmanifestationofpolyneuropathyindiabeticpatients.
TNF-α SUPPRESSANTS AND CLINICAL
DIABETIC POLYNEUROPATHY
Because beneﬁcial effects of TNF-α suppressants on di-
abetic polyneuropathy were conﬁrmed in animal models
[20–23], we were interested in exploring the clinical effects
of these suppressants. We previously reported the results of
a questionnaire study on diabetic polyneuropathy in approxi-
mately33,000diabeticpatientsintheTohokuareaofJapan[45].
Among these, 1228 patients were treated with troglitazone. To
observe the effect of troglitazone on diabetic polyneuropathy,
we retrospectively analyzed the data from the questionnaire.
As shown in Figure 3, the patients treated with troglitazone had
fewer subjective symptoms such as paresthesia, leg cramp, and
diarrheaorconstipationthanthosenottreatedwithtroglitazone
under the similar glycemic control. This result may imply that
troglitazone may be effective in ameliorating the symptoms of
diabetic polyneuropathy.TNF-α IN DIABETIC POLYNEUROPATHY 69
FIGURE 3
Frequency of symptoms of neuropathy in diabetic patients. The data of the questionnaire survey performed in Japan in 1998 [45]
were subanalyzed. The patients treated with troglitazone had less frequency of symptoms of diabetic neuropathy.
∗p <. 05; ∗∗p <. 01
FUTURE DIRECTION
From recent experimental and clinical studies, we con-
sider that augmented expression and production of TNF-α are
strongly implicated in the pathogenesis of diabetic polyneu-
ropathy and suppressants of TNF-α are beneﬁcial for alleviat-
ing signs and symptoms of this intractable disorder. However,
the precise mechanism of TNF-α in the pathogenesis of dia-
beticpolyneuropathyislargelyunknown.Forthefutureclinical
application of TNF-α suppressants in effective ways, further
studies are necessary to verify the role of TNF-α, for exam-
ple, by evaluating (1) the effects of TNF-α administration on
nerve blood ﬂow as well as MNCV, and (2) the effects of spe-
ciﬁc inhibition of TNF-α on nerve blood ﬂow and MNCV by
using speciﬁc antibodies or speciﬁc agents. TNF-α or TNF-α
receptor knockout animals may be also of use for this purpose.
If the active role of TNF-α is conﬁrmed, anti–TNF-α therapy
will be valuable as a fundamental for the treatment of diabetic
complications such as polyneuropathy.
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